Epizyme reported $231.2M in Loan Capital for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Abbott ABT:US $ 17547M 58M
Agios Pharmaceuticals AGIO:US $ 0.17M 0.08M
Amarin AMRN:US $ 0M 0M
Amgen AMGN:US $ 28458M 2671M
Avrobio Inc AVRO:US $ 0 0
Biogen BIIB:US $ 7269.2M 2M
Bluebird Bio BLUE:US $ 0M 0M
Cerulean Pharma CERU:US $ 0 0
Daiichi Sankyo 4568:JP Y 163347M 33148M
Eisai 4523:JP Y 49913M 5M
Epizyme EPZM:US $ 231.2M 691K
Exelixis EXEL:US $ 0M 0M
GlaxoSmithKline GSK:LN 20442M 2605M
Glaxosmithkline GSK:US $ 20442M 2605M
IONIS PHARMACEUT IONS:US $ 1240.7M 369.78M
Karyopharm Therapeutics KPTI:US $ 301.38M 59.58M
Macrogenics MGNX:US $ 0 0
Mirati Therapeutics MRTX:US $ 0M 0M
Novartis NOVN:VX SF 26491M 908M
Novartis NVS:US $ 26491M 908M
Regeneron Pharmaceuticals REGN:US $ 1979.2M 0.3M
Seattle Genetics SGEN:US $ 0M 0M
Spectrum Pharmaceuticals SPPI:US $ 0M 0M
Vertex Pharmaceuticals VRTX:US $ 524.92M 5.4M
Xencor XNCR:US $ 0M 0M